AHA 2019 The BETonMACE trial evaluating apabetalone did not reduce the primary composite efficacy outcome, nor key secondary outcomes, in T2DM patients with recent ACS and low HDL-c.
AHA 2019 This analysis of DAPA-HF shows that dapagliflozin consistently reduced worsening HF events and CV death and improved symptoms in patients with HFrEF, irrespective of diabetes status.
A post hoc analysis of ADVANCE and ADVANCE-ON data shows that a eGFR slope of -3 mL/min/1.73m² was associated with increased risk of clinical outcomes in patients with T2DM.
A systematic review and meta-analysis of four trials shows that SGLT2 inhibition reduces the risk for dialysis, kidney transplantation, or death due to kidney disease in T2DM patients.
Based on the CREDENCE renal outcomes trial, the FDA granted the approval of canagliflozin to treat diabetic kidney disease (DKD) and reduction of HF hospitalization in patients with T2DM and DKD.
Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.
In the ADDITION-Cambridge population-based study, 30% of participants achieved remission of T2DM after 5 years, mostly those who lost ≥10% body weight early in the T2DM disease trajectory.
CSI Paris Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.
In data of the Look AHEAD trial, the effects on CV risk factors of maintaining weight loss were compared with those of weight regain, in year 1 to 4 after a 1-year intensive lifestyle intervention.
Before listing the differences between the AHA/ACC 2018 and ESC/EAS 2019 dyslipidemia guidelines, prof. Ballantyne shares common themes and shared concept across the guidelines.
ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.